Cited 81 times in
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.